JP2024507414A - ウイルス感染症治療のためのrock2阻害剤 - Google Patents

ウイルス感染症治療のためのrock2阻害剤 Download PDF

Info

Publication number
JP2024507414A
JP2024507414A JP2023575684A JP2023575684A JP2024507414A JP 2024507414 A JP2024507414 A JP 2024507414A JP 2023575684 A JP2023575684 A JP 2023575684A JP 2023575684 A JP2023575684 A JP 2023575684A JP 2024507414 A JP2024507414 A JP 2024507414A
Authority
JP
Japan
Prior art keywords
ring
membered
group
alkyl
saturated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023575684A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024507414A5 (cg-RX-API-DMAC7.html
Inventor
ディー.ワクサル サミュエル
ウー ルイ
Original Assignee
グラビトン バイオサイエンス べスローテン フェンノートシャップ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by グラビトン バイオサイエンス べスローテン フェンノートシャップ filed Critical グラビトン バイオサイエンス べスローテン フェンノートシャップ
Publication of JP2024507414A publication Critical patent/JP2024507414A/ja
Publication of JP2024507414A5 publication Critical patent/JP2024507414A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2023575684A 2021-02-22 2022-02-22 ウイルス感染症治療のためのrock2阻害剤 Pending JP2024507414A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163152260P 2021-02-22 2021-02-22
US63/152,260 2021-02-22
PCT/US2022/017312 WO2022178420A1 (en) 2021-02-22 2022-02-22 Rock2 inhibitor for the treatment of viral infection

Publications (2)

Publication Number Publication Date
JP2024507414A true JP2024507414A (ja) 2024-02-19
JP2024507414A5 JP2024507414A5 (cg-RX-API-DMAC7.html) 2025-02-26

Family

ID=82931820

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023575684A Pending JP2024507414A (ja) 2021-02-22 2022-02-22 ウイルス感染症治療のためのrock2阻害剤

Country Status (8)

Country Link
US (1) US20240165116A1 (cg-RX-API-DMAC7.html)
EP (1) EP4301132A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024507414A (cg-RX-API-DMAC7.html)
KR (1) KR20240009918A (cg-RX-API-DMAC7.html)
CN (1) CN117529320A (cg-RX-API-DMAC7.html)
AU (1) AU2022224669A1 (cg-RX-API-DMAC7.html)
CA (1) CA3209240A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022178420A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202327608A (zh) * 2021-09-17 2023-07-16 北京泰德製藥股份有限公司 治療病毒感染的方法
CA3231781A1 (en) * 2021-09-18 2023-03-23 Beijing Tide Pharmaceutical Co., Ltd. Solid form of rho-associated protein kinase inhibitor or solvate thereof, preparation method and use thereof
US12637461B2 (en) 2022-10-18 2026-05-26 Pfizer Inc. Compounds for the activation of AMPK
WO2024220173A1 (en) * 2023-04-18 2024-10-24 Genosco Inc. Blood brain barrier penetrating selective inhibitors of rock2 protein kinases and uses thereof
EP4698528A1 (en) * 2023-04-18 2026-02-25 Genosco Inc. Selective inhibitors of rock2 protein kinases and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020525522A (ja) * 2017-06-30 2020-08-27 ベイジン タイド ファーマシューティカル カンパニー リミテッドBeijing Tide Pharmaceutical Co., Ltd. Rho−関連プロテインキナーゼ阻害剤、それを含む医薬組成物並びにその調製方法及び使用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3470137A (en) * 1967-02-14 1969-09-30 Du Pont Inter se copolymers of bicyclo(1.1.0)butanes
WO2015025172A1 (en) * 2013-08-22 2015-02-26 Mark David Charles 5-aryl-thiazol-2-yl-amine compounds and their therapeutic use
CA3155220C (en) * 2016-03-02 2024-01-16 Gilead Apollo, Llc Solid forms of a thienopyrimidinedione acc inhibitor and methods for production thereof
EP3308786A1 (en) * 2016-10-13 2018-04-18 ETH Zurich Fgfr regulaton for the treatment of viral infections
JP6593305B2 (ja) * 2016-11-09 2019-10-23 株式会社村田製作所 二次電池用電解液、二次電池、電池パック、電動車両、電力貯蔵システム、電動工具および電子機器
TWI804743B (zh) * 2019-06-25 2023-06-11 大陸商北京泰德製藥股份有限公司 治療特發性肺纖維化的方法
CN118772118A (zh) * 2020-08-31 2024-10-15 北京泰德制药股份有限公司 Rho相关蛋白激酶抑制剂的盐、其固体形式及其制备方法和用途
CA3231781A1 (en) * 2021-09-18 2023-03-23 Beijing Tide Pharmaceutical Co., Ltd. Solid form of rho-associated protein kinase inhibitor or solvate thereof, preparation method and use thereof
EP4434513A4 (en) * 2021-11-16 2025-11-19 Beijing Tide Pharmaceutical Co Ltd NANOCRYSTALLINE PREPARATION OF ROCK2 INHIBITOR AND ITS PREPARATION PROCESS
EP4561579A1 (en) * 2022-07-27 2025-06-04 Graviton Bioscience BV Rock2 inhibitors for the treatment of viral infections

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020525522A (ja) * 2017-06-30 2020-08-27 ベイジン タイド ファーマシューティカル カンパニー リミテッドBeijing Tide Pharmaceutical Co., Ltd. Rho−関連プロテインキナーゼ阻害剤、それを含む医薬組成物並びにその調製方法及び使用

Also Published As

Publication number Publication date
WO2022178420A1 (en) 2022-08-25
KR20240009918A (ko) 2024-01-23
CA3209240A1 (en) 2022-08-25
US20240165116A1 (en) 2024-05-23
EP4301132A4 (en) 2025-03-26
CN117529320A (zh) 2024-02-06
AU2022224669A1 (en) 2023-09-28
EP4301132A1 (en) 2024-01-10

Similar Documents

Publication Publication Date Title
US20240165116A1 (en) Rock2 inhibitor for the treatment of viral infection
KR100542536B1 (ko) 지도부딘,1592u89및3tc또는ftc의상승작용성복합제제
CN101990434B (zh) 用于治疗沙粒病毒感染的抗病毒药物
EP3437644B1 (en) Compounds for use in the treatment of pulmonary hypertension
EP3823957A1 (en) Inhibitors of hepatitis b virus
JP2024535095A (ja) タウロデオキシコリン酸またはその薬学的に許容可能な塩および抗ウイルス剤を有効成分として含有するコロナウイルス感染症-19(covid-19)治療用組成物
US20240041861A1 (en) Compositions and methods for treatment and prophylaxis of viral infections
US20260007673A1 (en) Rock2 inhibitors for the treatment of viral infections
EP3395344B1 (en) Medicine for treating heart failure
PT99434A (pt) Processo para a preparacao de composicoes farmaceuticas contendo derivados de xantina
CZ2001977A3 (cs) Kombinace účinných látek
JP2014532636A (ja) ウイルス感染の処置のためのヌクレオシドアナログおよび該処置に対する感受性を評価するための方法
EP1225904A2 (en) Combinations of lamivudine and entecavir for treatment of hepatitis b virus infection
EP1113803A1 (en) Antiviral combinations comprising lamivudine and abacavir
JPWO1997037657A1 (ja) イミダゾール誘導体を含有する抗hiv組成物
TWI230610B (en) Dosage kits and pharmaceutical compositions for treating HIV infections
HK40000144B (en) Compounds for use in the treatment of pulmonary hypertension
JPH0551567B2 (cg-RX-API-DMAC7.html)
HK1262939B (en) Medicine for treating heart failure
HK40000144A (en) Medicine
HK1262939A1 (en) Medicine

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250217

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250217

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260310

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260609

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260714